PARP1 and colorectal carcinoma: Of note, SENSMED-CRC-SCs were more efficiently targeted by MRE11i + RAD51i than SENSHIGH-CRC-SCs (Supplementary Fig. S7e), possibly due to higher PARP1 levels.